Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of KarXT and KarXT + KarX-EC in Youth With Schizophrenia or Autism-Related Irritability
2025-524062-16-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label trial of xanomeline and KarX-EC in schizophrenia and Autism Spectrum Disorder (ASD) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Treatment-emergent adverse events. Planned start Sep 2026; status: authorised.
02
Drugs
xanomelineKarX-EC
03
Conditions
schizophreniaAutism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2025-524062-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524062-16-00.